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Summary This study shows that combinations of bryostatin 1, a novel modulator of protein kinase C currently under clinical evaluation, with
the anti-oestrogenic agent tamoxifen caused a large synergistic enhancement of growth inhibition in P388 cells in vitro. The growth-inhibitory
effects of bryostatin 1 in the presence of non-inhibitory concentrations of tamoxifen were increased by approximately 200-fold, whereas
growth inhibition by tamoxifen in the presence of non-inhibitory concentrations of bryostatin 1 were increased over 30-fold. These data have
been confirmed by isobologram analysis. The precise mechanism underlying this effect is unknown, although preliminary data implicating
protein kinase C is presented. The magnitude of this synergistic effect, together with evidence of clinical responses seen when these agents
were given sequentially in ovarian cancer, merits further study.
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Bryostatin 1 is a macrocyclic lactone isolated from the marine
invertebrate Bugula neritina, a member of the phylum Ectoprocta
(Pettit et al, 1982). Bryostatin 1 exerts a wide variety ofbiological
effects, including antineoplastic activity, immunoenhancing
effects and haemopoietic stimulation. Bryostatin 1 showed
significant activity in vitro against several cell lines, including
leukaemia, lymphomas, melanoma, lung and renal tumours (Pettit
et al, 1982; Dale and Gescher, 1989; Hornung et al, 1992).
Although the precise mechanism of action of bryostatin 1 is
unknown, it is believed that the agent modulates protein kinase C
(PKC) (Berkow and Kraft, 1985).
The PKC proteins are a family of serine-threonine kinases that
are involved in a range ofcellular processes, including growth and
differentiation (Azzi et al, 1992; Gescher, 1992). The precise
mechanism by which activation ofPKC can elicit such a variety of
biological responses is unknown. However, it is likely that differ-
ences in activation, down-regulation and intracellular translocation
of individual PKC isoforms after activation may give rise to this
diversity ofeffects.
Bryostatin 1 shares many of the biological effects of known
activators of PKC, such as the phorbol esters (Dale and Gescher,
1989). It has been shown that cells made resistant to bryostatin 1
show reduced expression of PKC and decreased PKC activity
(Prendiville et al, 1994). A comparison ofthe effects ofbryostatin
1 and the phorbol esters, however, shows several important differ-
ences. Bryostatin 1 does not induce differentiation in human
bronchial epithelium (Jetten et al, 1989) and is not a tumour
promoter. Indeed, bryostatin 1 has been shown to inhibit the
tumour-promoting properties of phorbol esters (Hennings et al,
1987). These differences may arise because of differential activa-
tion, intracellular distribution or stabilization of the various
isoforms that make up the PKC family.
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Tamoxifen, a widely used anti-oestrogen, is also known to
interact with PKC. However, unlike bryostatin 1, tamoxifen is an
inhibitor ofthese kinases (O'Brian et al, 1988).
A phase I trial of bryostatin 1 (Jayson et al, 1995) showed
responses in ovarian cancer. After relapse, these patients showed
further responses to tamoxifen. These observations were unex-
pected and led to this investigation into a possible interaction
between these agents. The clinical situation cannot be easily
emulated, and a simplified study combining these agents in vitro
was therefore undertaken. Both these agents are known to modulate
PKC, and therefore the role ofthese kinases was also investigated.
MATERIALS AND METHODS
The cell lines used in this study were P388 (murine lymphocytic
leukaemia), P388 BR/D, a bryostatin-resistant cell line derived
from the parental P388 cells (Prendiville et al, 1994), A2780
human ovarian and the human breast cell lines, MCF-7 and BT-20.
These had been screened for mycoplasma and were free of infec-
tion. All chemicals and drugs were obtained from reputable
sources and were ofthe highest quality available. Bryostatin 1 was
isolated in the laboratory by one of the authors (GR Pettit).
Oestrogen and progesterone receptor levels were measured by
the clinical endocrinology service at the Christie Hospital,
Manchester, UK, using commercial ERICA and PgRICA kits
(Abbott Laboratories, UK).
Growth inhibition was determined using the MTT assay (Vistica
et al, 1991) with, unless otherwise stated, continuous exposure to
the drug. The analysis of the effect of drug combinations was
carried outby the isobologram method (Steel andPeckham, 1979).
PMA (phorbol 12-myristate 13-acetate)-activated PKC activity
was assayed by phosphorylation ofan acetylated peptide based on
myelin basic protein, Ac-MBP (4-14), (Yashuda et al, 1990), as
described previously (Prendiville et al, 1994). P388 cells (approxi-
mately 1 x 107 per assay) were rapidly pelleted, washed with ice-
cold phosphate-buffered saline, resuspended in ice-cold extraction
buffer (20 mm Tris, pH 7.5, 0.5 mM EDTA, 0.5% Triton X-100 and
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Table 1 The growth-inhibitory effects of bryostatin 1, phorbol 12-myristate
13-acetate (PMA), staurosporine and tamoxifen
Cell line Drugs IC50
P388 Bryostatin 1 34.5 ± 24.1 ng ml-' (n =
11)
P388BR/D Bryostatin 1 > 1 jg ml-'
P388 PMA 26 ±13 ng ml-' (n = 3)
P3988 BR/D PMA > 1 jg ml-,
P388 Staurosporine 8.2 ± 4.1 ng ml-' (n = 3)
P388BR/D Staurosporine 12.2 ± 4.5 ng ml-' (n = 2)
P388 Tamoxifen 3.5 ± 1.0 jg ml-' (n = 8)
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Figure 1 Isobologram analysis of the effect of combinations of bryostatin 1
and tamoxifen on the growth of P388 cells in vitro. The data points represent
the IC.0 concentration (concentrations required to produce a 50% inhibition of
growth). The shaded area represents the envelope of additivity as calculated
by methods I and 11 (Steel and Peckham, 1979)
25 ugml-1 aprotinin andleupeptin) and sonicated. PKC waspartly
purifiedbybinding to DEAE (diethylaminoethyl) cellulose, which
had been equilibrated with ice-cold wash buffer (20 mm Tris,
pH 7.5, 0.5 mm EDTA and 0.5 mm EGTA). PKC was collected as
a single fraction with ice-cold elution buffer (20 mm Tris, pH 7.5,
0.5 mM EDTA, 0.5 mM EGTA, 10 mm mercaptoethanol and 0.2 M
sodiumchloride). Enzyme activity was assayed in triplicate after a
5-min incubation at 30°C in a reaction mixture containing 20 mM
Tris, pH 7.5, 20 mm magnesium chloride, 1 mm calcium chloride,
20gM ATP, 0.2 ,uCi of [y-32P]ATP, 50 ,UM Ac-MBP (4-14),
0.25 mM EDTA, 0.25 mm EGTA, 5 mm ,B-mercaptoethanol and
0.1 M sodium chloride with 10 ,UM PMA, 0.28 mg ml-' phospha-
tidylserine and Triton X-100 mixed micelles. Negative control
levels were assayed by incubation with 20gM PKC inhibitor
[PKC (19-36)]. Reactions were terminated by spotting aliquots of
the reaction mixture onto individualphosphocellulose discs, which
were washed with 1% (v/v) phosphoric acid and water to remove
non-incorporated [,y-32P]ATP. Each phosphocellulose disc was
placed in a scintillation vial with scintillation fluid (10 ml)
for measurement of radioactivity in a Beckman (USA) LS 1801
scintillation counter. Conditions were adjusted to ensure that the
reaction was linear with respect to time ofincubation and concen-
tration of cells. This assay has previously shown excellent agree-
ment with phorbol binding assays (Prendiville et al, 1994).
RESULTS
The effect ofbryostatin 1, tamoxifen, staurosporine and PMA on
the growth of tumour cells in vitro is shown in Table 1. It can be
seen that the bryostatin-resistant cell line (P388BRID) is cross-
resistant to the PKC activator PMA, but not to tamoxifen.
Combinations ofbryostatin 1 and tamoxifen exhibited a marked
synergistic inhibition of the growth of P388 cells. Figure 1 shows
that 1 ,ug ml-1 tamoxifen potentiated the effect ofbryostatin 1 more
than 200-fold while 1 ng ml-' bryostatin 1 potentiated the effect of
tamoxifen by more than 30-fold. This isobologram shows the
effects ofcombinations ofbryostatin 1 and tamoxifen. The data are
the IC50 concentrations of each drug both individually (bryostatin,
39 ng ml-'; tamoxifen, 4 jg ml-I) and in combination. Ifthe agents
were simply actingadditively then the combination ofdrug concen-
trations that would cause a 50% decrease in cell growth would fall
on a straight linejoining the individual IC50 values. However, non-
linearity of survival curves generates an 'envelope of additivity'
Table 2 Effect of drug combinations on the growth of cells in vitro
Cell line Drug 1 Drug 2 Enhancement of
growth inhibition
P388 Bryostatin 1 (1 ng ml-') Tamoxifen 34
P388 Tamoxifen (1 jg ml-') Bryostatin 200
P388 Staurosporine (1 ng ml-') Tamoxifen 1.2
P388 Staurosporine (1 ng ml-') Bryostatin 1.7
P388 PMA (10 ng ml-') Tamoxifen 25
P388 Tamoxifen (1 jg ml-') PMA 3.9
P388BR/D Bryostatin 1 (100 ng ml-') Tamoxifen 1.0
The final column represents the IC50 of drug 2 (alone) divided by the IC5, of drug 2 when given in combination with a non-inhibitory
concentration of drug 1. The larger this value the greater the toxicity of the combination.
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Table 3 Effect of bryostatin 1 and tamoxifen, alone and in combination, on the PMA-activated PKC activity of P388 cells.
Bryostatin 1 (ng ml-1) Tamoxifen (gg ml-') Growth inhibition (%) Relative PKC activity (t= 24 h)
- - 0 1.0
0.1 - 0 28+6
1 - 0 62±8
10 - 30 0.6±0.8
30 - 50 0.5±0.5
- 0.2 0 52±7
1 15 90±11
- 4.1 50 1.2±1
0.1 1 20 157 ± 27
1 0.2 25 8±1
10 4 >90 0
30 1 > 90 0
All PKC activities are expressed relative to control P388 cells. The results are expressed as mean ± s.d. of triplicate samples. Growth
inhibition values were calculated from the isobologram curves. The activity of control cells was 0.133 ± 0.041 (n = 3) pmol 32p
incorporated per 9g protein.
(shaded area). If a combination of agents shows synergy (as in this
case), the curve will lie below the envelope ofadditivity.
It was also demonstrated that the synergistic effect was main-
tained even when drugs were given sequentially at times up to 24 h
apart (data not shown).
No synergy between tamoxifen and bryostatin 1 was observed
when the P388BR/D (bryostatin-l-resistant) cells, which have
reduced PKC expression, were incubated with tamoxifen in the
presence ofbryostatin 1 at concentrations up to 100 ng ml'. (IC50
tamoxifen alone, 5.4 gg ml-1; IC50 tamoxifen in the presence of
100 ng ml bryostatin 1, 5.1 ,ug ml-') (Table 2).
The PKC activator phorbol 12-myristate 13-acetate (PMA) also
potentiated the growth inhibitory effects of tamoxifen (Table 2).
This potentiation (25-fold) was similar with bryostatin I (34-fold)
under similar experimental conditions. However, tamoxifen at the
non-inhibitory concentration of 1 gg ml-' caused only a modest
(four-fold) increase in the growth-inhibitory effects of PMA
compared with that observed with bryostatin 1 (200-fold, Table 2).
Interestingly, the PKC inhibitor staurosporine did not enhance the
activity ofbryostatin 1 or tamoxifen (Table 2).
The roles of oestrogen and oestrogen receptors in this synergy
were studied. Two cell lines with different oestrogen receptor status
(MCF-7 receptor positive and BT-20 receptor negative) were shown
to have differential responses to tamoxifen (IC, 0.7 jig ml' and
3.3 jg ml-' respectively) but were insensitive to the growth-
inhibitory effects ofbryostatin 1 (IC50> 100 ng ml-'). Simultaneous
incubation with tamoxifen (1 jg ml-') did notresultingrowth inhibi-
tion by bryostatin 1 in either cell line at concentrations up to
100 ng ml-'. Combinations ofoestrogen andbryostatin 1 also showed
no enhancement ofgrowth inhibition in P388 cells. Furthermore, an
analysis of P388 cells showed no detectable oestrogen or proges-
terone receptor. These data provide evidence that oestrogen and the
oestrogen receptor are not involved in the synergy.
The role of PKC in the enhancement of drug sensitivity was
investigated. PKC activity attributable to PMA was measured
90 min and 24 h after treatment with tamoxifen and bryostatin 1.
The concentrations of drugs used were chosen to produce a range
of growth-inhibitory effects when given either as single agents in
combination (Table 3). All combinations and each individual drug
ablated PKC activity 90 min after addition of drug. However, the
PKC activity in cells treated with non- or weakly inhibitory
concentrations of drugs showed elevated PKC activities 24 h after
treatment (Table 3). This elevation ofPKC activity was substantial
and ranged from a 28-fold increase (bryostatin 1, 0.1 ng ml-') to a
90-fold increase for tamoxifen (1 jig ml-'). The relatively non-
inhibitory combination ofdrugs (bryostatin 0.1 ng ml-', tamoxifen
1 jig ml') showed an almost 160-fold increase in PKC activity at
24 hcompared withuntreated(control) cells, whereas more growth-
inhibitory combinations showed a loss ofPKC activity at 24 h.
DISCUSSION
Bryostatin 1 is believed to act by modulation ofcell signalling via
an interaction with PKC (Berkow and Kraft, 1985). PKC is an
attractive target for cancer chemotherapy as these kinases play a
central role in many cellular processes, including cell growth and
division. PKC consists ofa family ofserine-threonine kinases that
are activated by a number of factors. Activation is followed by
translocation and down-regulation. The fate ofindividual isoforms
is cell line dependent and influenced by a number of parameters,
including the nature ofthe activating species.
Phase I trials ofbryostatin 1 were undertaken in Manchester and
Oxford, UK, under the sponsorship of the Cancer Research
Campaign (Philip et al, 1993; Prendiville et al, 1993; Jayson et al,
1995). In the third ofthese phase I trials, bryostatin 1 was given as
a 24-hour intravenous infusion, weekly for 8 weeks. The dose-
limiting toxicity was myalgia, and this limited the recommended
dose for phase II evaluation to 25 jgml-2 per week. Four
responses were seen (n = 19), with two (one partial and one minor)
in women who had been heavily pretreated with chemotherapy for
advanced ovarian carcinoma. Disease progression was noted in
these patients 4 months and 6 months after completion of bryo-
statin 1 treatment. The patient who showed the minor response
to bryostatin 1 was treated with intravenous paclitaxel, which
afforded a further partial response of 4 months duration. Both
patients were subsequently treated with tamoxifen (20 mg day-'
for 6 months); the patients who had initially showed a partial
response to bryostatin 1 also achieved a radiological partial
response to tamoxifen of 14 months duration, while the second
patient also showed stabilization ofdisease for 10 months.
British Journal ofCancer(1998) 77(2), 216-220 0CancerResearchCampaign 1998Effects ofbryostatin 1 and tamoxifen on P388 cells 219
The response rate in patients with chemoresistant ovarian carci-
noma treated with tamoxifen (20 mg day-') is 7% (Ahlgren et al,
1993). Thus, the responses, initially to bryostatin 1 and subse-
quently to tamoxifen, seen in these patients, although anecdotal,
were unexpected and prompted this investigation into combining
these agents. The clinical situation, in which bryostatin 1 and
tamoxifen were given sequentially and some months apart, cannot
be emulated in vitro. This initial study was carried out using
combinations of these agents added simultaneously in vitro. Both
agents are known to interact with PKC and the initial hypothesis
was that both agents may exert their growth-inhibitory effects by
interaction with a common isoform or a series ofisoforms that are
expressed within responsive tumours. In order to examine this, an
in vitro study was designed using the bryostatin-sensitive murine
P388 cell line and its bryostatin-resistant subclone (P388 BRID),
which has been shown to express reduced levels of PKC
(Prendiville et al, 1994).
It was observed that addition ofcombination ofbryostatin 1 and
tamoxifen to P388 cells caused increased growth inhibition
(Figure 1). Tamoxifen can reduce the concentration ofbryostatin 1
required to inhibit growth in the P388 cell line by over two orders
of magnitude. Similarly, bryostatin 1 can enhance the growth-
inhibitory effects of tamoxifen by over 30-fold. It is unclear why
there is a difference in the magnitude of the synergy (200-fold
compared with 30-fold), depending upon which drug is added at
the non-inhibitory concentration. Interestingly, the synergistic
effect was elicited irrespective of whether the agents were added
simultaneously or up to 24 h apart.
Evidence for the involvement of PMA-activated PKC in this
synergy is seen in the bryostatin-resistant P388 BRJD cell line.
This line has been shown to have reduced (95% reduction) PKC
activity and isoenzyme expression (Prendiville et al, 1994). No
synergy was observed in this cell line. Further evidence for the
involvement of PKC can be seen through the use of PMA (Table
2). This potent activator of PKC enhanced the activity of tamox-
ifen to a level (25-fold) similar to that for bryostatin 1 (34-fold).
However, tamoxifen had only a modest (fourfold) effect on the
growth-inhibitory properties of PMA. This difference between
PMA and bryostatin 1 is not understood but may arise by modula-
tion of different PKC isoforms or by altered translocation and
down-regulation. Bryostatin 1 and PMA have been shown to
produce different effects on these processes (Levine et al, 1991;
Hocevar et al, 1992; Kennedy et al, 1992).
The lack of effect of the PKC inhibitor staurosporine on the
growth inhibition induced by bryostatin 1 or tamoxifen does not
support a role for PKC. However, the complexity and diversity of
the PKC family and the cell line-specific effects observed with
PKC modulators may explain the lack ofeffect ofthis agent.
Under the conditions used in this study, tamoxifen did not
induce sensitivity to bryostatin 1 in the MCF-7 and BT-20 cell
lines. Thus, it is unlikely that oestrogen receptor status is a major
factor in the observed synergy, as neitherthe MCF-7 nor the BT-20
cell lines (which are classical receptor-positive and receptor-nega-
tive cell lines, exhibiting the expected differential effects towards
tamoxifen) showed increased sensitivity when treated with combi-
nations of bryostatin 1 and tamoxifen. Further evidence against
hormonal involvement is the lack ofdetectable oestrogen receptor
expression in the P388 cell line.
The known interactions ofboth tamoxifen and bryostatin 1 with
PKC make these signalling pathways potential mechanisms under-
lying this synergy. Treatment of P388 cells with bryostatin 1 and
tamoxifen caused large changes in the PMA-activated PKC
activity, as determined by incorporation of 32p into the synthetic
peptide (Table 3). There was a loss of PKC activity 90 min after
addition of drugs. This could arise either by tamoxifen-mediated
inhibition of PKC or by down-regulation of PKC by bryostatin 1.
A similarrapid loss ofPKC has been observed in several cell lines
after treatment with bryostatin 1 (Kennedy et al, 1992). A large
increase in PKC activity was observed 24 h after treatment with
non-toxic levels ofbryostatin 1 and tamoxifen. However the use of
higher, more growth-inhibitory drug concentrations resulted in a
sustained loss of PKC activity. The mechanism underlying these
changes in PKC activity is currently under investigation. Work is
currently ongoing to determine the fate of individual isoforms of
PKC after treatment with these agents.
The potentiation ofthe growth-inhibitory effects ofbryostatin 1
and tamoxifen is large and, if reproduced in other cell lines and
more importantly in vivo, may have clinical applications. The
present study shows that the P388 cell line, which is sensitive to
bryostatin 1, experiences a substantial (200-fold) enhancement of
growth inhibition when bryostatin 1 and tamoxifen are used in
combination. Preliminary results indicate that PKC may be
involved in this synergy. Extrapolation of this experimental study
to the clinical observations must be approached with caution,
particularly because of the differences in scheduling. Further
studies to elucidate the roles of activation and translocation of
individual PKC isoforms are needed to fully elucidate the involve-
ment ofthese enzymes in this process.
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